Intervention Review

You have free access to this content

Isoniazid for preventing tuberculosis in non-HIV infected persons

  1. Marek Smieja1,*,
  2. Catherine Marchetti2,
  3. Deborah Cook3,
  4. Fiona M Smaill4

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 5 MAY 2003

DOI: 10.1002/14651858.CD001363

Database Title

Additional Information

How to Cite

Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001363. DOI: 10.1002/14651858.CD001363.

Author Information

  1. 1

    McMaster University, Pathology and Molecular Medicine, Hamilton, Ontario, Canada

  2. 2

    Missisauga, Ontario, Canada

  3. 3

    McMaster University, Dept. of Clinical Epidemiology & Biostatistics, Hamilton, Ontario, Canada

  4. 4

    McMaster University, Department of Pathology and Molecular Medicine, Faculty of Health Sciences, Hamilton, Ontario, Canada

*Marek Smieja, Pathology and Molecular Medicine, McMaster University, L-424, St. Luke's Wing, St. Joseph's Healthcare, Hamilton, Ontario, L8N 4A6, Canada. smiejam@mcmaster.ca.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 20 JAN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (58K)Standard (272K)Full (318K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Isoniazid versus placebo, Outcome 1 Active tuberculosis.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Isoniazid versus placebo, Outcome 2 Extra-pulmonary tuberculosis.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Isoniazid versus placebo, Outcome 3 TB deaths.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Isoniazid versus placebo, Outcome 4 Hepatitis.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Isoniazid versus placebo, Outcome 5 Hepatitis-related deaths.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Isoniazid versus placebo, Outcome 6 Total deaths.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Isoniazid 6 vs 12 months, Outcome 1 Active tuberculosis.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Isoniazid 6 vs 12 months, Outcome 2 Hepatitis.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Isoniazid 6 vs 12 months, Outcome 3 Active tuberculosis in highly compliant.
[Analysis 3.1]
Analysis 3.1. Comparison 3 INH 6 months vs placebo, Outcome 1 Active tuberculosis.
[Analysis 4.1]
Analysis 4.1. Comparison 4 INH 12 months+ vs placebo, Outcome 1 Active tuberculosis.
[Analysis 5.1]
Analysis 5.1. Comparison 5 High compliance (>80%) INH vs placebo, Outcome 1 Active tuberculosis.
View Full Article (HTML) Summary (58K)Standard (272K)Full (318K)